Moreover, transcriptomic and immune profiling were performed on 158 tumor biopsies from melanoma patients treated with anti-PD-1 monotherapy or combined anti-PD-1 and anti-CTLA-4 therapy. This evidence concerns the gene CTLA4 and neoplasm.